Antimüllerian hormone levels decrease in women using combined contraception independently of administration route

Kallio, S.; Puurunen, Johanna; Ruokonen, Aimo; Vaskivuo, Tommi; Piltonen, Terhi; Tapanainen, Juha S.

doi:10.1016/j.fertnstert.2012.11.034

Cited by 110 publications

(83 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the best static screening tests for ovarian reserve are AMH testing and ultrasonographic AFC [16,19,20]. Our recent findings of lower AFC numbers and AMH in adult DM [6], and now in PM patients, reinforced the diagnosis of premature reduced ovarian reserve in idiopathic inflammatory myopathies.…”

Section: Discussionmentioning

confidence: 83%

Reduced ovarian reserve in patients with adult polymyositis

et al. 2015

View full text Add to dashboard Cite

Polymyositis (PM) affects female gender during reproductive age; however, there is no study assessing ovarian reserve in these patients to evaluate ovarian reserve markers in PM. Eight female patients with PM (Bohan and Peter criteria, 1975) with aged 18-40 years, followed at our tertiary centre from March 2011 to May 2014, were invited to participate. They were age-matched with 16 healthy individuals (control group). All were evaluated at early follicular phase of menstrual cycle. Follicle stimulating hormone (FSH), estradiol, inhibin B, anti-Müllerian hormone (AMH) serum levels (ELISA) and sonographic antral follicle count (AFC) were determined. PM patients and controls had comparable mean age (31.4 ± 6.5 vs. 30.7 ± 6.2 years, P = 0.946), ethnicity and socioeconomic class (P > 0.05). PM mean age of onset was 27.3 ± 6.5 years and disease duration of 6.5 ± 4.1 years. Menstrual cycles were alike in both groups with a similar frequency of age at menarche, gynaecological age, duration and length of menstrual cycle (P > 0.05). The median serum level of AMH was significantly lower in PM compared to controls [0.7(0.3-3.4) vs. 3.1(1.4-4.0), P = 0.021]. AMH levels ≤1 ng/mL (50 vs. 6.3 %, P = 0.024) and very low AFC (37.5 vs. 6.3 %, P = 0.037) were significantly in PM patients versus controls. The other hormones (FSH, inhibin B and estradiol levels) were similar between both groups (P > 0.05). The present study was the first to identify subclinical ovarian dysfunction in PM patients during reproductive ages. Further study is necessary to assess the possible role of PM-related factors that may influence the ovarian function of these patients.

show abstract

Section: Discussionmentioning

confidence: 83%

Reduced ovarian reserve in patients with adult polymyositis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Indeed, AMH levels are stable across the menstrual cycle and are not affected by pregnancy or treatment with gonadotropinreleasing hormone agonists. In addition, although an effect of combined oral contraceptive pill on ovarian reserve has been described (Bentzen et al 2012, Deb et al 2012, Kallio et al 2013, its use seems to be associated with minimal suppression of the later FSH-dependent stages of follicle development (Arbo et al 2007, Streuli et al 2008, Sowers et al 2010, Li et al 2011, Shaw et al 2011. It is still debated if clinical and behavioral variables, such as BMI and smoking habit, may influence AMH plasma levels.…”

Section: Amh and Fertilitymentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

“…29 The contraceptive effect is primarily established by the suppression of pituitary gonadotropins secretion, which results in decreased ovarian activity, namely the inhibition of follicular growth and ovulation. 29 In this study, we observed no significant statistical difference in AMH concentrations between users and nonusers of hormonal contraceptives and our findings are in agreement with the results of Steiner et al 30 and Li et al 31 Alternatively, two recent reports showed reduced AMH concentrations in hormonal contraceptive users. 29,32 It is also known that smoking exerts adverse effects on reproductive function.…”

Section: Discussionmentioning

confidence: 99%

Validation of an immunoassay for anti-Müllerian hormone measurements and reference intervals in healthy Brazilian subjects

et al. 2014

View full text Add to dashboard Cite

Background: Anti-Müllerian hormone is marker of ovarian and testicular reserve. The clinical use of this hormone requires proper standardization of reference intervals. The aims of this study were to validate the Anti-Müllerian hormone Gen II immunoassay, to establish Anti-Müllerian hormone reference intervals in healthy subjects, and to evaluate the influence of hormonal contraceptives, smoking, and body mass index on Anti-Müllerian hormone. Methods: The validation of the Anti-Müllerian hormone Gen II assay (Beckman Coulter Company, TX, USA) was performed using a simplified protocol recommended by Clinical Laboratory Standard Institute. One-hundred and thirtythree healthy females and 120 males were prospectively selected for this study. Results: The analytical and functional sensitivities of the Anti-Müllerian hormone Gen II immunoassay were 0.02 and 0.2 ng/mL, respectively. Intra-assay coefficients ranged from 5.2 to 9.0%, whereas inter-assay precision ranged from 4.6 to 7.8% at different concentrations. In females, Anti-Müllerian hormone showed progressive decline with increasing age (r ¼ À0.4, p < 0.001), whereas in males, age showed no influence on Anti-Müllerian hormone concentrations. In females, Anti-Müllerian hormone concentrations did not differ between users and non-users of hormonal contraceptives, smokers, and non-smokers and obese and lean individuals. However, there was a negative and significant correlation between Anti-Müllerian hormone and body mass index in males (r ¼ À0.3, p ¼ 0.008). Conclusions: Anti-Müllerian hormone Gen II assay was reliable for determining serum Anti-Müllerian hormone concentrations. Anti-Müllerian hormone concentrations declined with aging and presented a wide inter-individual variability. The lack of influence of hormonal contraceptives, smoking, and obesity on Anti-Müllerian hormone in both sexes allowed us to refine the normative concentrations for the Brazilian population.

show abstract

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route

Cited by 110 publications

References 52 publications

Reduced ovarian reserve in patients with adult polymyositis

Reduced ovarian reserve in patients with adult polymyositis

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Validation of an immunoassay for anti-Müllerian hormone measurements and reference intervals in healthy Brazilian subjects

Contact Info

Product

Resources

About